Evaluating different doses of Panzyga for children with CIDP

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and efficacy of various dose regimens of Panzyga in pediatric patients diagnosed with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). The study will include children aged 2 to 17 years who exhibit functional impairment due to CIDP. Participants will receive different doses of Panzyga, and their responses will be monitored to determine the most effective regimen. The trial follows a structured approach to ensure that the results are reliable and can inform future treatment options for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥2 years and ≤17 years.
2. Patients with a diagnosis of CIDP based on European Academy of Neurology/Peripheral Nerve Society (EANPNS) 2021 guidelone \[1\]
3. Clinical history of functional impairment due to CIDP, corresponding to an mRS score ≥2, but ≤5.
4. Voluntarily given written informed consent (provided by patient's parent or legal guardian) and assent (provided by the patient, if age appropriate per Independent Ethics Committee \[IEC\]/Institutional Research Board \[IRB\] requirements).

Exclusion Criteria:

1. Patients with previously diagnosed CIDP who lack any CIDP symptoms.
2. Patients with a known history of inherited neuropathy or a family history of inherited neuropathy.
3. Patients who have previously failed immunoglobulin therapy for CIDP.
4. Patients who received immunoglobulin or plasma exchange (PEX) within eight weeks prior to the Baseline Visit (washout phase). However, if a patient has clinical evidence of confirmed CIDP relapse during the washout phase (consistent with an increase in mRS of ≥1), they are eligible for trial enrolment.
5. Patients with a history of deep vein thrombosis (DVT) in the past year, or pulmonary embolism ever.
6. Patients on unstable (change in prescribed dose within the last eight weeks) corticosteroids or rituximab use.
7. Patients with known or suspected hypersensitivity, anaphylaxis, or severe systemic response to immune-globulins, blood or plasma derived products, or any component of PANZYGA.
8. Female patients who are breastfeeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method while on the study (acceptable methods of birth control for this study include: intrauterine device \[IUD\], hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical cap).
9. Presence of medical history information or clinical symptoms suggestive of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) infections.
10. Severe liver and/or kidney disease (alanine aminotransferase \[ALT\] \> 3 × upper limit of normal \[ULN\]; aspartate aminotransferase \[AST\] \> 3 × ULN; and/or creatinine levels \>44 µmol/L for children ages 2-3 years, \>62 µmol/L for children ages 4-10 years, and \>89 µmol/L for children ages 11-17 years.
11. Presence of medical history information or clinical symptoms suggestive of immunoglobulin (IgA) deficiency and antibodies against IgA.
12. History of alcohol or drug abuse in the previous year, per Investigator's opinion.
13. Unable or unwilling to comply with the study protocol.
14. Receipt of any other investigational medicinal product (IMP) within three months before study entry or participating in another interventional clinical study. Prior participation in an observational or open-label study involving an approved product may be allowed but require prior consultation with the Medical Monitor to assess eligibilty.
15. Any other condition(s) that, in the Investigator's opinion, makes it undesirable for the patient to participate in the study or may interfere with protocol compliance.

Where it's running

• Octapharma Research Site
  Birmingham, Alabama, United States Recruiting
• Octapharma Research Site
  Orange, California, United States Recruiting
• Octapharma Research Site
  Louisville, Kentucky, United States Recruiting
• Octapharma Research Site
  Philadelphia, Pennsylvania, United States Recruiting
• Octapharma Research Site
  Houston, Texas, United States Recruiting
• Octapharma Research Site
  Charlottesville, Virginia, United States Recruiting

Study contacts

• Study coordinator: Theresa Conklin
• Email: ctgov@clinicalresearchmgt.com
• Phone: 866-337-1868

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Panzyga to prevent major infections during autoimmune therapy

  This Phase 3 trial tests whether Panzyga can help prevent serious infections in adults with hypogammaglobulinemia who are receiving B-cell depletion therapy for autoimmune or rheumatic conditions.

  Recruiting at 11 sites Phase 3 Octapharma · Glendale, Arizona and 24 other locations · NCT07220915

• Treatment of acute hereditary angioedema with a plasma-derived C1 inhibitor

  This study is testing a new treatment using a plasma-derived C1 inhibitor to see if it can help people with hereditary angioedema manage their symptoms better than a placebo.

  Recruiting at 6 sites Phase 3 Octapharma · Centennial, Colorado and 26 other locations · NCT06361537

• Evaluating a new treatment for patients resistant to heparin during heart surgery

  This study is testing a new treatment called Atenativ to see if it can help heart surgery patients who don't respond to heparin feel better and have safer surgeries.

  Recruiting at 22 sites Phase 3 Octapharma · Stanford, California and 26 other locations · NCT06096116

• Using Nuwiq to manage bleeding in women and girls with Hemophilia A during surgery

  This study is testing if Nuwiq can help prevent bleeding during major surgeries for women and girls aged 12 and older with mild to moderate Hemophilia A.

  Recruiting at 13 sites Phase 4 Octapharma · San Antonio, Texas and 15 other locations · NCT05936580

• Using Nuwiq to manage bleeding in hemophilia A patients during major surgery

  This study is testing if Nuwiq can help prevent bleeding during major surgery for boys and men over 12 with severe hemophilia A who are already using another treatment called emicizumab.

  Recruiting at 17 sites Phase 4 Octapharma · Dallas, Texas and 17 other locations · NCT05935358

• Assessing Atenativ for patients with congenital antithrombin deficiency during surgery or delivery

  This study tests whether Atenativ can help prevent blood clots in patients with congenital antithrombin deficiency during surgery or childbirth.

  Recruiting at 30 sites Phase 3 Octapharma · Washington D.C., District of Columbia and 29 other locations · NCT04918173

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.